- The Department of Justice finalized medical cannabis reclassification to Schedule III, enabling major tax deductions for state-licensed operators.
- Recreational cannabis remains in Schedule I, maintaining the split between medical benefits and adult-use federal restrictions.
- Immigration authorities maintain that marijuana-related conduct carries risks of deportation or inadmissibility for non-citizens despite reclassification.
(UNITED STATES) — The Department of Justice finalized the federal reclassification of medical cannabis from Schedule I to Schedule III on April 22, 2026, redrawing tax rules for state-licensed medical operators while leaving federal immigration risks in place for non-citizens.
The change moved two categories into Schedule III: FDA-approved drug products containing marijuana, and marijuana products regulated under a qualifying state-issued medical marijuana license. Recreational cannabis remains in Schedule I, leaving adult-use businesses under the older federal tax and criminal framework.
Acting Attorney General Todd Blanche framed the order as part of a broader policy shift ordered by President Donald Trump. “The Department of Justice is delivering on President Trump’s promise to expand Americans’ access to medical treatment options. This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information,” Blanche said on April 24, 2026.
President Trump had directed agencies to speed the move in an executive order issued on December 18, 2025, describing it as a “common-sense approach” to state-regulated medical programs. The final order now marks the first federal acknowledgment of cannabis as having accepted medical use since the Controlled Substances Act of 1970.
The most immediate effect falls on taxes. State-licensed medical operators can deduct ordinary business expenses beginning in the 2026 tax year, ending the Section 280E treatment that had barred deductions for costs such as rent, payroll and marketing.
| India | China | ROW | |
|---|---|---|---|
| EB-1 | Dec 15, 2022 ▼107d | Apr 01, 2023 | Current |
| EB-2 | Sep 01, 2013 ▼317d | Sep 01, 2021 | Current |
| EB-3 | Dec 15, 2013 ▲30d | Aug 01, 2021 ▲47d | Jun 01, 2024 |
| F-1 | Sep 01, 2017 | Sep 01, 2017 | Sep 01, 2017 |
| F-2A | Jan 01, 2025 ▲153d | Jan 01, 2025 ▲153d | Jan 01, 2025 ▲153d |
That relief reaches directly into cash flow. The prior rules often pushed effective tax rates above 70%, and the shift to Schedule III allows medical businesses to keep more revenue for operations, hiring and reinvestment.
The Justice Department’s final order also encouraged the Secretary of the Treasury to “consider providing retrospective relief from Section 280E liability” for prior years in which operators held valid state medical licenses. That language stops short of automatic relief, but it opens the door to review of earlier tax periods.
Businesses that want federal recognition now face a short compliance window. State-licensed medical marijuana companies have a 60-day period, closing June 22, 2026, to file for DEA registration if they want prioritized processing and legal continuity during the transition.
The Federal Medical Cannabis Reclassification does not erase the split inside the industry. A dispensary or producer serving a state medical program can benefit from the new federal treatment, while an adult-use operator selling recreational cannabis remains subject to Section 280E and the older Schedule I rules.
Louisiana offers a measure of the money involved. Medical cannabis sales in the state reached $90.9 million for the fiscal year ending June 30, 2025, a 77% increase, illustrating the size of the licensed medical market now positioned to benefit from lower federal tax burdens.
Medical operators also stand to gain in areas beyond taxes. The change improves profitability and, according to recent 2026 rulings in Delaware, strengthens access to standard banking and bankruptcy protections that had been harder to secure while marijuana sat in Schedule I across the board.
Patients could see a different set of effects. The new classification eases research restrictions and supports more traditional pharmaceutical development and physician oversight, particularly for products that now fit within the federal medical framework.
Federal immigration policy has not moved with the tax change. USCIS and the Department of Homeland Security have not modified their enforcement posture, and marijuana-related conduct still carries consequences for non-citizens even after the move to Schedule III.
As of May 8, 2026, the USCIS Policy Manual continued to say that marijuana-related conduct, including work in a state-licensed facility, can create a conditional bar to Good Moral Character for naturalization. Because marijuana remains a federally controlled substance, non-citizens can still face detention, deportation or inadmissibility tied to personal use or industry employment.
That leaves the country with two legal tracks operating at once. Federal Medical Cannabis Reclassification brings tax relief, more room for research and broader commercial protections to parts of the medical market, but recreational cannabis remains under Schedule I and immigration authorities still treat marijuana conduct as a live federal issue.
Official records on the change and its aftermath appear through the Justice Department at [justice.gov/news](https://www.justice.gov), the USCIS Policy Manual at [uscis.gov/policy-manual](https://www.uscis.gov/policy-manual/volume-12-part-f-chapter-5), the Department of Homeland Security at [dhs.gov/newsroom](https://www.dhs.gov/newsroom), and the Federal Register at [govinfo.gov](https://www.govinfo.gov), including Vol. 91, No. 81, April 28, 2026.
